Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2014; 20(8): 1923-1934
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.1923
Table 1 Targeting apoptosis in colorectal cancer: An overview of current clinical trials
DrugTargetClinical1Ref.
Smac mimeticsIAPsPhase I (NCT01573780)[49,139]
Survivin peptide vaccinesurvivinPhase I-II (NCT00108875)[140,141]
OblimersenBcl-2Phase I (NCT00004870)[142,143]
DulanerminDR4/5 dualPhase Ib (NCT00671372)[86]
TigatuzumabDR5Phase I[144]
CS-1008DR5Phase I (NCT01220999)[145]
HGS-ETR1DR4Preclinical in vivo[79]
HGS-ETR2DR5Phase I (NCT00428272)[79,146]
rhApo2L/TRAILDR4/DR 5Phase I-II[147]
(NCT00819169)
ConatumumabDR5Phase II (NCT01327612)[148]
ABT-263Bcl-2/Bcl-xlPhase I (NCT00891605, NCT01009073)[24]
ABT-737Bcl-2/Bcl-xlPreclinical in vivo[25,26,30]
GossypolPan-Bcl2Preclinical in vivo[149]